Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ContraVir Pharmaceuticals, Inc. (CTRVP)

Other OTC . Currency in USD
Add to watchlist
0.00
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CTRVP

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference

      EDISON, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced that its CMO, Dr. Todd Hobbs, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021, at 4:00 p.m. Eastern Time. The virtual presentation will be

    • GlobeNewswire

      All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431

      EDISON, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced results from a Drug-Drug Interaction (‘DDI’) study with its lead drug candidate, CRV431. CRV431 targets several isoforms of cyclophilins which comprise a family of enzymes involved in process

    • GlobeNewswire

      Additional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program

      Pro-C3 and ALT reductions point to anti-inflammatory and antifibrotic effects of CRV431PK-PD models successfully predict early reductions in Pro-C3 and ALTHepion’s proprietary AI-POWR™ and machine learning accurately predict CRV431 respondersAnti-fibrotic gene expression signature revealed in bioinformatic analyses Phase 2b activities initiated EDISON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artifi

    Advertisement
    Advertisement